Arbutus Biopharma (ABUS) Total Current Liabilities (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Total Current Liabilities for 17 consecutive years, with $5.1 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities fell 73.73% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (down 73.73% YoY) and the FY2025 annual result came in at $6.0 million, down 61.54% from the prior year.
• Total Current Liabilities retreated to $5.1 million in Q1 2026 per ABUS's latest filing, from $6.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for ABUS reached as high as $32.9 million in Q4 2022 and fell as low as $5.0 million in Q2 2025.
• A 5-year average of $19.7 million and a median of $22.3 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 384.22% — and 2025, when it slumped 77.77%.
• Year by year, Total Current Liabilities stood at $32.9 million in 2022, then sank by 31.56% to $22.5 million in 2023, then sank by 30.55% to $15.6 million in 2024, then sank by 61.54% to $6.0 million in 2025, then declined by 15.0% to $5.1 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $5.1 million, $6.0 million, and $5.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.